Zoetis Inc. (ZTS) Gross Margin: 70.75%
Is Zoetis Inc.’s gross margin high or low?
Zoetis Inc.'s gross margin of 70.75% is in line with its 5-year average of 68.46%, near the high end of its 5-year range (66.79%–70.49%).
The gross margin for Zoetis Inc. (ZTS) is 70.75% as of Wednesday, June 10, 2026. It is above its 12-month average by 1.37% (69.79%).
ZTS Gross Margin Chart
ZTS Average Gross Margin Chart
ZTS Current vs Average Gross Margin Chart
ZTS Gross Margin Metrics
GROSS MARGIN
70.75%
GROSS MARGIN AVG TTM
69.79%
GROSS MARGIN AVG 3Y
68.91%
GROSS MARGIN AVG 5Y
68.46%
GROSS MARGIN AVG 10Y
66.64%
GROSS MARGIN AVG 15Y
64.93%
GROSS MARGIN AVG 20Y
64.74%
CURRENT VS TTM AVG
+1.37%
CURRENT VS 3Y AVG
+2.67%
CURRENT VS 5Y AVG
+3.35%
CURRENT VS 10Y AVG
+6.16%
CURRENT VS 15Y AVG
+8.96%
CURRENT VS 20Y AVG
+9.28%
ZTS Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | — | 70.75% | 69.79% | 68.91% | 68.46% |
| Centene Corporation (CNC) | $31.94B | 14.93% | 11.28% | 11.33% | 11.71% |
| Agilent Technologies, Inc. (A) | $37.17B | 53.00% | 53.36% | 52.95% | 53.14% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 26.11% | 30.59% | 32.75% | 33.07% |
| DexCom, Inc. (DXCM) | $29.24B | 61.84% | 60.23% | 62.09% | 63.91% |
| Biogen Inc. (BIIB) | $29.00B | 69.77% | 73.30% | 74.61% | 77.63% |
| Veeva Systems Inc. (VEEV) | $26.73B | 74.95% | 75.03% | 73.28% | 73.00% |
| Humana Inc. (HUM) | $43.78B | 14.01% | 14.54% | 16.14% | 17.03% |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 62.05% | 61.42% | 60.55% | 59.83% |
| Waters Corporation (WAT) | $23.83B | 55.02% | 58.60% | 58.69% | 58.45% |
Gross Margin Analysis
Gross Margin
70.8%
(Revenue - COGS) / Revenue
Zoetis Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. Gross Margin FAQ
- What is the gross margin for Zoetis Inc. (ZTS)?
- The gross margin for ZTS stock is 70.75%.
- Is Zoetis Inc.'s gross margin high or low?
- Zoetis Inc.'s gross margin of 70.75% is in line with its 5-year average of 68.46%, near the high end of its 5-year range (66.79%–70.49%).
- What is the TTM average gross margin for Zoetis Inc. (ZTS)?
- The TTM average gross margin for ZTS stock is 69.79%.
- What is the 3Y average gross margin for Zoetis Inc. (ZTS)?
- The 3Y average gross margin for ZTS stock is 68.91%.
- What is the 5Y average gross margin for Zoetis Inc. (ZTS)?
- The 5Y average gross margin for ZTS stock is 68.46%.
- What is the 10Y average gross margin for Zoetis Inc. (ZTS)?
- The 10Y average gross margin for ZTS stock is 66.64%.
- What is the 15Y average gross margin for Zoetis Inc. (ZTS)?
- The 15Y average gross margin for ZTS stock is 64.93%.
- What is the 20Y average gross margin for Zoetis Inc. (ZTS)?
- The 20Y average gross margin for ZTS stock is 64.74%.
Zoetis Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 70.49% |
| 2024-12-31 | 69.10% |
| 2023-12-31 | 68.28% |
| 2022-12-31 | 67.77% |
| 2021-12-31 | 68.31% |
| 2020-12-31 | 66.79% |
| 2019-12-31 | 65.70% |
| 2018-12-31 | 65.18% |
| 2017-12-31 | 64.88% |
| 2016-12-31 | 64.30% |
| 2015-12-31 | 62.27% |
| 2014-12-31 | 62.86% |
| 2013-12-31 | 62.11% |
| 2012-12-31 | 62.71% |
| 2011-12-31 | 59.96% |
| 2010-12-31 | 58.21% |
| 2009-12-31 | 61.67% |
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck